Navigation Links
Life Technologies Acquires BAC BV, Expands Capabilities in Bioprocessing
Date:1/22/2013

CARLSBAD, Calif., Jan. 22, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced its acquisition of BAC BV, a privately held company based in the Netherlands, and a leader in the discovery, development and manufacture of protein purification products. The acquisition expands Life's capabilities and product offerings in the growing market of biopharmaceutical research and manufacturing.

"Our acquisition of BAC BV positions Life Technologies as a leading provider of end-to-end solutions that are widely utilized in the bioprocess workflow," said Tony Hunt , head of BioProduction at Life Technologies. "Combining BAC's current portfolio and pipeline with our pre-existing portfolio expands Life's product offering and enables us to compete more fully across the protein purification market. We intend to immediately integrate the portfolios and leverage the Life commercial platform to drive accelerated growth in this market."

Bioprocessing is the production and analytical testing of biologically-based therapeutics, which are developed in cultured cells or microorganisms, and include drugs, vaccines, biosimilars, and gene and cell therapies. Life Technologies' Gibco® brand is the market leader in cell culture media, a position it has held for 50 years, and the company more recently integrated its POROS® brand of chromatography resins for purification of therapeutic products into the Bioproduction portfolio.

The acquisition expands Life's existing portfolio by adding BAC BV's unique set of innovative and proprietary affinity ligands to the company's world-class POROS® resins. Affinity ligands are molecules capable of binding with very high affinity to specific proteins, and are typically attached to chromatography resins in a production-scale, bio-purification process.

Life customers will benefit from a streamlined approach to protein purification with tailored end-to-end solutions. In addition to Gibco® culture media, POROS® resins and the BAC BV affinity ligand portfolio for protein purification, Life also offers the Applied Biosystems® SEQ rapid molecular kits for contaminant and impurity testing of bio-therapeutic products.  

"We are looking forward to developing and providing unique, enabling products from our combined portfolios and capabilities to our purification customers," said Laurens Sierkstra, Ph.D., chief executive officer of BAC BV. Sierkstra and an additional 34 employees will join Life Technologies. Current BAC BV facilities, a manufacturing site in Naarden and R&D facility in Leiden, Netherlands, will remain in operation. 

Financial terms of the deal were not disclosed. The tuck-in acquisition of BAC BV is expected to be neutral to the company's overall ROIC three years after close.

About Life Technologies
Life Technologies Corporation (NASDAQ:  LIFE) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today's most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum, with more than 50,000 products for agricultural biotechnology, translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent™, Applied Biosystems®, Invitrogen™, Gibco®, Ambion®, Molecular Probes® and Novex®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.7 billion in 2011. Visit us at our website: http://www.lifetechnologies.com.

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies Contact
Suzanne Clancy
760-602-4545
858-205-4235 (mobile)
suzanne.clancy@lifetech.com


'/>"/>
SOURCE Life Technologies Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Neptune Technologies & Bioressources Inc. To Contact The Firm
2. Statement by Life Technologies Board of Directors
3. Brain State Technologies to Host Open House and Demonstrate Their Revolutionary Technology
4. BioSpecifics Technologies Corp. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
5. France & Germany Blood Banking Market: Innovative Technologies and Emerging Business Opportunities in New Research Report at ReportsnReports.com
6. Adaptive Biotechnologies launches clonoSEQ, a more sensitive, accurate assay to detect minimal residual disease (MRD) in blood-based cancers.
7. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
8. Medical Marijuana, Inc. Portfolio Company CanChew BioTechnologies Inc. Updates and Expands Free Product Trial
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
10. Nu Skin Enterprises Enters Into Agreement To Acquire NOX Technologies
11. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... launch of the Supplyframe Design Lab . Located in Pasadena, Calif., the ... future of how hardware projects are designed, built and brought to market. , ...
(Date:6/23/2016)... June 23, 2016  Blueprint Bio, a company dedicated ... the medical community, has closed its Series A funding ... . "We have received a commitment from ... we need to meet our current goals," stated ... the runway to complete validation on the current projects ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 Perimeter ... Platforms, Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... market will generate revenues of $17.98 billion in 2016. ... DVTEL Inc, a leader in software and hardware technologies ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
Breaking Biology News(10 mins):